HPV

The most widespread STI in the world: nearly everyone encounters it, the great majority clear it unaided, and a vaccine protects against the dangerous types.

Illustration: HPV

The infection

Human papillomaviruses are a family of more than two hundred viruses, around forty of which infect genital and oral mucous membranes. Low-risk types cause genital warts; high-risk types, chiefly 16 and 18, cause almost all cervical cancer and a large share of anal, throat, vulval, vaginal and penile cancers. Infection is so common that it can be regarded as an ordinary event in sexual life: in nine cases out of ten the body clears the virus within one to two years with no consequence.

Key facts

OrganismDNA virus, over 200 types, around 40 genital
Low-risk types6 and 11: responsible for 90% of genital warts
High-risk typesMainly 16 and 18: cervical, anal and throat cancers
Cleared naturallyAbout 90% of infections within two years
ScreeningHPV test on a cervical sample from age 30; self-sampling increasingly offered
Treating the virusNot possible: lesions are treated, not the infection
VaccineYes, highly effective, recommended from age 11 for girls and boys

How it is transmitted

The virus passes through simple skin and mucosal contact in the genital area, without penetration. That is why condoms, which do not cover the whole contact area, protect only partly — though they still reduce risk substantially. Transmission through oral sex explains the rise in HPV-related throat cancers. Infection usually occurs in the first years of sexual activity.

Symptoms

In the overwhelming majority of cases there are no symptoms at all. Low-risk types cause warts: small painless growths, single or clustered, on the vulva, penis, scrotum, around the anus or inside the vagina, appearing weeks to months after exposure. High-risk types never cause symptoms: they work silently and are found only by screening.

Testing

There is no validated screening test for men. For women, cervical screening now relies on the HPV test, which is more sensitive than conventional cytology: in most guidelines, cytology every three years from 25 to 29, then an HPV test every five years from 30 to 65. Vaginal self-sampling, now offered in several countries, allows women who do not attend screening to test at home.

Treatment

No treatment removes the virus itself: the immune system does that in most cases. What is treated are the manifestations. Warts are treated with immune-modulating cream, cryotherapy, laser or surgery, with a real risk of recurrence. Precancerous cervical lesions found by screening are either monitored or removed by a simple excision procedure that prevents progression to cancer.

If left untreated

Persistence of a high-risk type over several years can produce precancerous lesions and then cancer, chiefly of the cervix but also the anus, oropharynx, vulva, vagina and penis. The interval between infection and cancer is long, typically ten to twenty years — and it is precisely that interval that makes screening so effective.

Prevention

After a diagnosis

Worth remembering

A positive HPV result never reveals when or from whom the infection came. The virus can lie dormant for years, and finding it in a settled relationship is not evidence of anything.

A little history

Genital warts were described by Greek and Roman physicians — the word "condyloma" comes from the Greek for "knob" — and already linked to sexual relations. In 1842, in Verona, Domenico Rigoni-Stern noticed that cervical cancer was almost unknown among nuns and common among married women and prostitutes: the first epidemiological evidence of a sexually transmitted cause. In 1907 Giuseppe Ciuffo showed that warts are transmitted by a cell-free filtrate, hence by a virus.

The screening smear, developed by George Papanicolaou between the 1920s and the 1940s, pushed back cervical cancer wherever it was applied, without the cause yet being known. It was Harald zur Hausen who, against the prevailing view that blamed the herpes virus, proposed papillomaviruses in 1976, then isolated HPV 16 in 1983 and HPV 18 in 1984 from cervical tumours: between them they cause 70% of cases. He received the Nobel Prize in 2008.

The vaccine relies on "virus-like particles", empty shells with no genetic material, a technique developed in 1991 by Ian Frazer and Jian Zhou in Brisbane, alongside American teams. Gardasil was approved in 2006, Australia launched the first national programme in 2007, and the nine-valent vaccine arrived in 2014. In 2020 the WHO adopted a strategy to eliminate cervical cancer; since 2022 it accepts that a single dose protects.

Country by country

The medicine is the same everywhere, but access, prevention programmes, what is free of charge and which services are responsible differ completely. Each country below has its own page.

Select a country to open its detailed page.

Britain and Ireland

United Kingdom

A single-dose school programme since 2023, HPV primary screening, and a national target to eliminate cervical cancer.

Ireland

A free school programme for girls and boys, a catch-up scheme, and HPV primary screening since 2020.

North America

United States

Routine vaccination at 11 or 12, catch-up to 26, and screening that now allows self-collection.

Canada

Free school programmes in every province, and a shift to HPV primary screening with self-sampling led by British Columbia.

Australia and New Zealand

Australia

Single-dose vaccination, universal self-collection for screening, and a credible path to eliminating cervical cancer.

New Zealand

A gender-neutral school programme, and HPV self-testing as the standard screening method since 2023.

South Asia

India

Cervical cancer is a leading cause of cancer death in women, and a domestically produced vaccine has changed what is possible.

Pakistan

A very high cervical cancer burden met, in 2025, by the country's first national HPV vaccination campaign.

South-East and East Asia

Singapore

A subsidised school programme for girls, and HPV testing every five years from 30.

Malaysia

A free school programme since 2010, and a self-sampling HPV screening model built for hard-to-reach women.

Philippines

School-based vaccination for girls, and screening that relies mainly on visual inspection.

Hong Kong

A free school programme for girls since 2019, and screening every three or five years depending on the test.

Africa

South Africa

A school programme for grade five girls since 2014, but an unusually sparse screening policy for adults.

Nigeria

HPV vaccination entered routine immunisation in 2023, one of the largest such introductions anywhere.

Kenya

HPV vaccination in routine immunisation since 2019, and screening built into primary care.

Ghana

Screening through visual inspection, with HPV vaccination introduced into the national programme.

Uganda

One of the earlier African countries to introduce the vaccine, in 2015, with screening through visual inspection.

Zambia

A long-established national screening programme built on visual inspection, and vaccination since 2019.

The Caribbean

Jamaica

School-based vaccination for girls, and screening that relies on cytology at public clinics.

Trinidad and Tobago

Free vaccination offered since 2013, and screening through public health centres.

← All infections The general page on STIs →

Who to see for this problem?

The page Who to see, and when gives, symptom by symptom, the right professional — family doctor, urologist, gynaecologist, sex therapist, psychologist — and the emergencies that cannot wait.

Further reading

Links to official or reference sources. They open in a new tab.

Page checked in September 2026. The instruments cited can change: if in doubt, confirm with the official source given.

Test what you have just read

Five questions, and every answer is somewhere on this page. Nothing is recorded: the score stays in your browser.

Loading the quiz…

Locate this page in the site map

A question, a correction, a suggestion? Write to us.